Paul Saultier, Gérard Michel, Anne Sirvent, Cécile Renard, Marie-Dominique Tabone, Guy Leverger, André Baruchel, Cécile Pochon, Catherine Paillard, Charlotte Jubert, Stéphane Ducassou, Marilyne Poirée, Marion Strullu, Mony Fahd, Sandrine Visentin, Arthur Stérin, Dominique Plantaz, Justyna Kanold, Virginie Gandemer, Alexandre Theron, Nicole Raus, Sandrine Thouvenin-Doulet, Carine Domenech, Julie Berbis, Pascal Auquier, Jean-Hugues Dalle

Hemasphere. 2026 Jan 19;10(1):e70298. doi: 10.1002/hem3.70298. PMID: 41560847; PMCID: PMC12813855.

https://pubmed.ncbi.nlm.nih.gov/41560847/

Abstract

Hematopoietic stem cell transplantation (HSCT) is a curative treatment for high-risk childhood leukemia but may lead to chronic graft-versus-host disease (cGvHD), a severe long-term complication. This study analyzed data from the LEA cohort, including 446 childhood leukemia survivors treated with allogeneic HSCT. The standardized cGvHD evaluation, using the NIH consensus criteria, was conducted 8.7 ± 0.3 years post-HSCT. Long-term cGvHD was reported in 21% of patients (9% mild, 7% moderate, 5% severe), primarily affecting eyes, skin, lungs, and mouth, with some cases involving multiple organs. Most patients with long-term cGvHD were untreated (84%), while 11% received systemic and 5% local treatments. cGvHD was associated with other long-term complications. Administration of anti-thymocyte globulin was a significant determinant (OR 0.6, 95% CI 0.4-0.99, P = 0.045). Long-term cGvHD showed a marked detrimental effect on the quality of life (QoL), even after adjusting for the other long-term complications. The SF-36 physical and psychological adjusted composite scores in patients with versus without cGvHD were 50 ± 2 versus 55 ± 1 (P = 0.01) and 38 ± 2 versus 43 ± 1 (P = 0.01), respectively. Even mild and moderate forms significantly affected the QoL, especially on psychological dimensions. These findings support standardized cGvHD evaluation and management to improve long-term outcomes of transplanted childhood leukemia survivors.

Abstract

Consult other publications

45. Genomics of Long-Term Complications of Childhood Leukemia : Rationale and Design of the GenLEA Study

44. Hearing loss in French survivors of childhood and adolescent leukemia: impact on quality of life and schooling difficulties

43. Long-term kidney complications in childhood leukemia survivors: a study from the Childhood and Adolescent Leukemia (LEA) project

42. How I treat long-term survivors of childhood acute leukemia

41. Educational outcomes in siblings of childhood leukemia survivors: Factors associated with school difficulties and comparison with general population

40. Impact of childhood leukemia on siblings: their long-term perception of family functioning and its relationship with their psychosocial characteristics using structural equation modeling

39. Misconceptions and beliefs around hormone replacement therapy after childhood hematopoietic stem cell transplantation: A qualitative study among women leukemia survivors

38. Ovarian Function and Spontaneous Pregnancy After Hematopoietic Stem Cell Transplantation for Leukemia Before Puberty: An L.E.A. Cohort Study

37. Symptomatic osteonecrosis in French survivors of childhood and adolescent leukemia: a clinical and MRI study of LEA cohort

36. The uterine volume is dramatically decreased after hematopoietic stem cell transplantation during childhood regardless of the conditioning regimen

35. Brothers and sisters of childhood acute leukemia survivors: Their long-term quality of life and its determinants

34. Bone mineral density evolution and its determinants in long-term survivors of childhood acute leukemia: a L.E.A. study

33. Testosterone deficiency in men surviving childhood acute leukemia after treatment with hematopoietic stem cell transplantation or testicular radiation: an L.E.A. study

32. Quality of life in parents of childhood leukemia survivors. A French Childhood Cancer Survivor Study for Leukemia study.

31. Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia.

30. Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors’ cohort: a comparison with controls from the French population.

29. Adolescence and Socioeconomic Factors: Key Factors in the Long-Term Impact of Leukemia on Scholastic Performance—A LEA Study.

28. Metabolic Syndrome Among Leukemia Survivors: Still Delineating the Risk.

27. A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers – DeNaCaPST programme.

26. Late effects in survivors of infantile acute leukemia: a study of the L.E.A program.

25. Metabolic syndrome in long-term survivors of childhood acute leukemia treated without hematopoietic stem cell transplantation: an L.E.A. study.

24. Employment in French young adult survivors of childhoodleukemia: an LEA study (for Leucemies de l’Enfant et de l’Adolescent—childhood and adolescent leukemia)

23. The Impact of Donor Type on Long-Term Health Status and Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Leucémie de l’Enfant et de L’Adolescent Study.

22. Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study.

21. Educational and occupational outcomes of childhood cancer survivors 30 years afterdiagnosis: a French cohort study.

20. Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

19. Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study.

18. Quality of life in minor siblings of childhood leukemia survivors, long-term after diagnosis: A LEA study (for Leucemies de l’Enfant et de l’Adolescent – childhood and adolescent leukemia).

17. Late cardiomyopathy in childhood acute myeloid leukemia survivors: an L.E.A. study.

16. Childhood cancer survivor cohorts in Europe.

15. Health status and quality of life of long-term survivors of childhood acute leukemia: the impact of central nervous system irradiation.

14. Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort).

13. Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study.

12. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.

11. Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.

10. Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood.

9. A French Cohort of Childhood Leukemia Survivors: Impact of Hematopoietic Stem Cell Transplantation on Health Status and Quality of Life.

8. Adherence to Leukemia Maintenance Therapy: A Comparative Study Among Children, Adolescents, and Adults.

7. The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): Development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer.

6. Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-UpStudy (LEA).

5. Bone mineral density in adult-survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities.

4. Quality of life in a heterogeneous sample of caregivers of cancer patients: an in-depth interview study.

3. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia.

2. Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.

1. Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation.